PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089965
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089965
According to SPER Market Research, the microcarrier market is estimated to reach USD 4.07 billion by 2030 with a CAGR of 10.2%. There is higher risk of virus outbreak due to climate change and increasing population. This creates opportunities for microcarrier market to grow.
The outburst of COVID-19 infections at global level forced the governments to declare nation-wide lockdowns and norms for social distancing. The small and large players in pharmaceuticals focused on developing vaccines and other therapies against SARS-CoV-2 Research and development quickly escalated and were largely unaffected by the lockdowns and restrictions due to the support and funding. Demand for cell culture products also increased including microcarrier products. Cell culture is an important part of vaccine development which has increased the demand for microcarrier products.
Rapidly increasing population, close proximity between animals and humans have created favorable conditions for virus outbreaks. This increases the demand for cell culture to develop cell-based vaccines. There is a higher risk of a pandemic in future creating urgent need for cell-based vaccines due to higher efficiency, large production capacity and shorter lead time. Clinical studies have also suggested cell-based vaccines as safe and effective for use in humans.
R&D in cell biology is an expensive process involving reagents and equipment of higher quality and precision in results. The high-quality standards issued by regulatory authorities increases the cost of the research. Thus, small players and academic institutes cannot afford to carry out this research which restraints the growth of this market in the forecast period.
Monoclonal antibodies are increasing in demand for targeted delivery for cancer treatments and immune diseases. The monoclonal antibodies are administered at higher doses thus, production is also required equally high. This creates growth opportunities for microcarriers.
Based on product, market has been segmented into Consumables (Media [Sera/Serum-based Media, Serum-free Media, Other Media], Reagents, Microcarriers [Collagen-coated Microcarriers, Cationic Microcarriers, Protein-coated Microcarriers, Untreated Microcarriers, Other Microcarriers]), Equipment (Bioreactors [Single-use Bioreactors, Stainless-steel Bioreactors], Culture Vessels, Filtration and Separation Equipment, Cell Counters, Other Equipment)
Based on application, the market is segmented into Biopharmaceutical Production (Vaccine Production, Therapeutic Protein Production), Cell and Gene Therapy, Tissue Engineering and Regenerative Medicine, Other Applications
Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations & Contract Manufacturing Organizations, Academic & Research Institutes, Cell Banks
Pharmaceutical & Biotechnological companies have the largest share of this market by end user due to changing regulatory scenarios of cell-based vaccines and rising awareness for cell-based vaccines for its benefits.
North America owns the largest share of this market owing to increasing R&D activities, technological advancements, increasing investments and funding in cell-based research and presence of leading players of this market.